Trial Profile

A retrospective study assessing the incidence of de novo DSA formation in kidney transplant recipients maintained on twice-daily immediate-release tacrolimus versus those maintained on once-daily extended-release tacrolimus in the first 2 years post-transplant

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Aug 2022 New trial record
08 Jun 2022 Primary endpoint treatment failure defined as a composite of de novo DSA formation, biopsy-proven acute rejection (BPAR), graft failure, or death at 24 months has not been met according to the results presented at the 2022 American Transplant Congress
08 Jun 2022 Preliminary results presented at the 2022 American Transplant Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com